AKT1 and cancer: Importantly, enzastaurin has a cooperative effect with gefitinib and is able to overcome and revert the resistance to gefitinib in cancer cells resistant to this anti-EGFR drug, likely due to the ability of enzastaurin to inhibit the Akt and VEGF pathways, directly responsible for the escape mechanisms activated in tumours resistant to EGFR inhibitors.